Inactive Instrument
DUCAT VENTURES Stock London S.E.
Stocks
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| 08/09 | OptiBiotix Health plc Provides Update on SweetBiotix Product Range | CI |
| 02/09 | Corero wins deal; Talisman kicks off Tirzzit drilling | AN |
| Market Cap | 5.94M 8.05M 6.92M 6.51M 11.08M 763M 11.14M 77.12M 29.84M 390M 30.22M 29.56M 1.24B | P/E 2024 |
-9.76x | P/E 2025 | -1.76x |
|---|---|---|---|---|---|
| Enterprise Value | 4.9M 6.64M 5.71M 5.37M 9.15M 630M 9.2M 63.65M 24.63M 322M 24.94M 24.4M 1.02B | EV / Sales 2024 |
19.4x | EV / Sales 2025 | 5.09x |
| Free-Float |
88.62% | Yield 2024 * |
-
| Yield 2025 | - |
| 16/09/25 | OptiBiotix Health : Financial document (interims 2025) | PU |
| 30/06/25 | OptiBiotix Health : Annual Report (ar2024) | PU |
| 30/06/25 | OptiBiotix Health : Financial document (prelims 2024) | PU |
| 27/09/24 | OptiBiotix Health : Results Report | PU |
| 28/06/24 | OptiBiotix Health : Results Report | PU |
| Manager | Title | Age | Since |
|---|---|---|---|
Stephen O'Hara
CEO | Chief Executive Officer | 66 | 05/08/2014 |
David Blain
DFI | Director of Finance/CFO | 65 | 01/11/2024 |
Sofia Kolyda
CTO | Chief Tech/Sci/R&D Officer | 53 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Sofia Kolyda
BRD | Director/Board Member | 53 | 04/07/2018 |
Stephen O'Hara
BRD | Director/Board Member | 66 | 05/08/2014 |
Richard Davidson
CHM | Chairman | 75 | 01/01/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.02% | +1.26% | +41.37% | +105.18% | 69.19B | ||
| -1.94% | -5.51% | +30.36% | +73.07% | 62.97B | ||
| -1.11% | +2.78% | -14.86% | +375.59% | 27.27B | ||
| -4.92% | -3.22% | -3.90% | -17.87% | 24.78B | ||
| -0.93% | -0.81% | +29.69% | +14.38% | 25.8B | ||
| -1.11% | -1.15% | +22.23% | -17.05% | 20.11B | ||
| +6.04% | +7.25% | +233.25% | +383.12% | 18.47B | ||
| -1.43% | -2.43% | -8.12% | +515.88% | 14.88B | ||
| -2.27% | +1.37% | +53.01% | +160.83% | 14.29B | ||
| Average | -0.59% | +0.74% | +42.56% | +177.01% | 30.86B | |
| Weighted average by Cap. | -0.38% | +0.11% | +37.55% | +139.53% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 870K 1.18M 1.01M 953K 1.62M 112M 1.63M 11.3M 4.37M 57.11M 4.43M 4.33M 182M | 1.17M 1.58M 1.36M 1.28M 2.18M 150M 2.19M 15.14M 5.86M 76.54M 5.93M 5.8M 244M |
| Net income | -1.8M -2.45M -2.1M -1.98M -3.37M -232M -3.39M -23.44M -9.07M -118M -9.18M -8.98M -377M | -3.89M -5.27M -4.53M -4.26M -7.26M -500M -7.3M -50.51M -19.54M -255M -19.79M -19.36M -813M |
| Net Debt | -739K -1M -861K -810K -1.38M -94.91M -1.39M -9.59M -3.71M -48.51M -3.76M -3.68M -154M | -1.04M -1.4M -1.21M -1.14M -1.94M -133M -1.95M -13.46M -5.21M -68.07M -5.28M -5.16M -217M |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
















